Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.
Elanco Animal Health develops, manufactures and markets animal health products for farm animals and pets. News about ELAN commonly covers operating and financial results, product launches in pet health and livestock health, and regulatory actions involving animal medicines and parasite-control products.
Company updates also include capital-structure disclosures, investor conference presentations, and governance changes tied to Elanco's board and public-company operations. Product-specific developments have included the Advantage brand for dogs and emergency-authorized livestock treatments such as Negasunt Powder and Tanidil.
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022. Jeff Simmons, the president and CEO, is scheduled for a fireside chat at 2:50 p.m. Eastern time.
A live audio webcast of the event will be accessible via the company’s investor website, with a replay available for 90 days.
Elanco Animal Health has released its 2021 Environmental, Social and Governance (ESG) Report detailing advances in sustainability and health initiatives. The report highlights efforts in workforce diversity with goals to increase women's leadership representation to 42% by 2023, and People of Color to 20%. Environmental impact is addressed by reducing emissions by 8% since 2020 and transitioning to renewable energy. Elanco also launched a global Animal Welfare Policy and improved access to veterinary care for 20 million farm animals in East Africa.
Elanco Animal Health reported a Q2 2022 revenue of $1,177 million, an 8% decrease year-over-year. The company’s net loss was $22 million, an improvement from $210 million last year. Adjusted net income reached $177 million with an adjusted EPS of $0.36. Full-year revenue guidance is now $4,465 to $4,550 million. Adjusted EBITDA for Q2 was $300 million, with margins improving to 25.5%. Amid macroeconomic challenges, Elanco emphasizes its strong pipeline, including new products set for market launch.
Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2022 financial results on Monday, August 8, 2022. A conference call will take place at 8:00 a.m. eastern time for detailed discussion of its performance. Investors and media can access a live webcast from Elanco's website, with a replay available shortly after the call. Elanco is committed to innovating animal health products and services, enhancing animal health, and delivering value to stakeholders.
Summary not available.
Elanco Animal Health has launched the "Unleash Joy" anthem and a music video featuring popular pets to promote their Seresto® collars, which offer eight months of flea and tick protection. The campaign emphasizes responsible pet ownership while encouraging pet owners to enjoy summer activities. Veterinarian David Gosche highlights the balance between fun and the risks of flea and tick-borne diseases during summer. Owners can share their pets' summer adventures on Instagram using the hashtag #SerestoJoinTheJoy.
Elanco Animal Health (NYSE: ELAN) will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 13-14, 2022. CFO Todd Young will be featured in a fireside chat on June 13 at 6:20 p.m. ET. Investors can access a live audio webcast via Elanco's investor website, with a replay available for 30 days.
Elanco Animal Health (NYSE: ELAN) will attend the Stifel 2022 Jaws and Paws Conference on June 1, 2022. CEO Jeff Simmons is scheduled to participate in a fireside chat at 3:00 p.m. ET. A live audio webcast of the event will be accessible on Elanco’s investor website, with a replay available for 30 days.
Elanco Animal Health reported Q1 2022 revenue of $1,225 million, a 1% decline year-over-year, but a 2% increase in constant currency. Net income stood at $48 million, up from a $61 million loss in Q1 2021. Adjusted EPS was $0.36, slightly down from $0.37. The company updated its full-year revenue guidance to a range of $4,700-$4,755 million, affected by foreign exchange rates. A strategic alliance with Royal DSM for Bovaer, a methane-reducing product, aims to generate significant future revenue. Despite some market pressures, Elanco remains confident in its growth strategy.
Elanco and Royal DSM have formed a strategic alliance to enhance sustainability in livestock farming by developing the methane-reducing product, Bovaer®, in the U.S. Elanco gains exclusive rights to commercialize the product, which has the potential for over US$200 million in annual revenue in the U.S. alone, contributing to the Global Methane Pledge goal of a 30% emission reduction by 2030. Royal DSM will benefit from royalty income and increased production capacity, promoting a significant environmental impact through reduced methane emissions from cattle.